首页> 外文期刊>Journal of Medicinal Chemistry >Structure-activity relationship studies of 4-(2-(diphenylmethoxy)ethyl)-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
【24h】

Structure-activity relationship studies of 4-(2-(diphenylmethoxy)ethyl)-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.

机译:4-(2-(二苯甲氧基)乙基)-1-苄基哌啶衍生物及其N-类似物的结构活性关系研究:O-和N-类似物的评估及其与单胺转运蛋白的结合。

获取原文
获取原文并翻译 | 示例
           

摘要

In our effort to develop a pharmacotherapy for the treatment of cocaine addiction, we embarked on synthesizing novel molecules targeting the dopamine transporter (DAT) molecule in the brain as DAT has been implicated strongly in the reinforcing effect of cocaine. Our previously developed DAT-selective piperidine analogue, 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine, was the basis for our current structure-activity relationship (SAR) studies exploring the significance of the contribution of the benzhydryl O- and N-atoms in these molecules in interacting with the DAT. Thus, we replaced the benzhydryl O-atom with an N-atom, altered the location of the benzhydryl N-atom to an adjacent position, and in one other occasion converted the benzhydryl O-ether linkage into an oxime-type derivative. Furthermore, we also evaluated the important contribution of the piperidine N-atom to binding by altering its pK(a) value chemically. Novel analogues were tested for potency in inhibiting [3H]WIN 35,428, [3H]citalopram, and [3H]nisoxetine binding at the DAT, serotonin transporter (SERT), and norepinepherine transporter (NET). [3H]DA was used to measure DA reuptake inhibition. The results indicated that the benzhydryl O- and N-atoms are exchangeable for the most part. On the other hand, an enhanced interaction with the SERT was observed when the benzhydryl N-atom moved to an adjacent position (21a; DAT (IC(50)) = 19.7, SERT (IC(50)) = 137 nM, NET (IC(50)) = 1111 nM). In either cases, further alkylation of the N-atom reduced the activity for the transporter. The presence of a powerful electron-withdrawing cyano group in compound 5d expectedly produced the most potent and selective ligand for the DAT (DAT (IC(50)) = 3.7 nM, DAT/SERT = 615). Selected compounds were further analyzed in the dopamine reuptake inhibition assay. Preliminary behavioral assessment of some of the selected compounds in mice indicated that these compounds are much less stimulating when compared with cocaine at comparable doses. In drug-discrimination studies these selected compounds incompletely generalized from the cocaine stimulus in mice trained to discriminate 10 mg/kg cocaine from vehicle.
机译:在开发治疗可卡因成瘾的药物疗法的努力中,我们着手合成靶向脑中多巴胺转运蛋白(DAT)分子的新型分子,因为DAT与可卡因的增强作用密切相关。我们先前开发的DAT选择性哌啶类似物4- [2-(2-(二苯基甲氧基)乙基] -1-苄基哌啶是我们目前的结构活性关系(SAR)研究的基础,该研究探讨了苯甲基O-和这些分子中的N原子与DAT相互作用。因此,我们用一个N原子取代了苯甲基O原子,将苯甲基N原子的位置改变为一个相邻的位置,并在另一种情况下将苯甲基O-醚键转化为肟型衍生物。此外,我们还评估了哌啶N原子通过化学改变其pK(a)值对结合的重要作用。测试了新型类似物在DAT,5-羟色胺转运蛋白(SERT)和去甲肾上腺素转运蛋白(NET)上抑制[3H] WIN 35,428,[3H]西酞普兰和[3H]尼西西汀结合的效力。 [3H] DA用于测量DA再摄取抑制。结果表明,苯甲基O-和N-原子大部分是可交换的。另一方面,当苯甲基N原子移动到相邻位置时,观察到与SERT的相互作用增强(21a; DAT(IC(50))= 19.7,SERT(IC(50))= 137 nM,NET( IC(50))= 1111 nM)。在这两种情况下,N原子的进一步烷基化都会降低转运蛋白的活性。化合物5d中强力吸电子氰基的存在有望产生DAT的最有效和选择性的配体(DAT(IC(50))= 3.7 nM,DAT / SERT = 615)。在多巴胺再摄取抑制试验中进一步分析了所选化合物。对某些选定化合物在小鼠中的初步行为评估表明,与可比较剂量的可卡因相比,这些化合物的刺激性要小得多。在药物区分研究中,这些选择的化合物在训练可从媒介物中区分出10 mg / kg可卡因的小鼠中,从可卡因刺激中未完全泛化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号